Cover Image
市場調查報告書

印度的醫藥品、醫療產業(季度更新報告)

India Pharmaceuticals and Healthcare Report Q4 2016

出版商 BMI Research 商品編碼 191492
出版日期 內容資訊 英文 120 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
印度的醫藥品、醫療產業(季度更新報告) India Pharmaceuticals and Healthcare Report Q4 2016
出版日期: 2016年08月10日 內容資訊: 英文 120 Pages
簡介

印度的醫藥品產業的收益規模,預計從2014年的160億美元,到2015年擴大11.7%,達到170億美元。還有醫療產業,預計從2014年的830億美元,到2015年成長12.4%,成為900億美元。

本報告提供印度的製藥、醫療產業結構和最新趨勢相關分析、今後10年的產業規模的動向估計、產業課題(風險)和未來商機(利潤)相關評估、政府的政策、規定、宏觀經濟環境、主要企業簡介等資訊彙整,為您概述為以下內容。

BMI的見解

SWOT分析

  • 政治
  • 經濟
  • 業務風險

產業預測

  • 醫藥品市場預測
  • 醫療市場預測
  • 處方藥市場預測
  • 專利藥市場預測
  • 學名藥市場預測
  • 一般用(OTC)醫藥品市場預測
  • 醫藥品的對外貿易情形
  • BMI的預測方案相關主要風險

宏觀經濟預測

  • 經濟分析

產業的風險/利潤、等級

  • 亞洲:風險/利潤、等級
  • 印度:風險/利潤、等級
    • 利潤
    • 風險

市場概況

產業的趨勢與發展

  • 流行病學
  • 醫療部門
  • 醫療部門的發展
  • 醫療保險
  • 研究開發(R&D)
  • 臨床實驗
  • 生技仿製藥
  • 傳統藥物

法規的發展

  • 醫藥品的廣告
  • 醫藥品安全性監視(藥物安全檢測)
  • 知識產權的保護體制
  • 價格政策
  • 強制許可證

競爭環境

  • 學名藥品產業
  • 產業的主要動向
  • 醫藥品的流通結構
  • 醫藥品的零售部門

企業簡介

  • Aurobindo Pharmaceutical
  • Cipla
  • Dr. Reddy's Laboratories
  • GlaxoSmithKline
  • Merck & Co
  • Novartis
  • Pfizer
  • Ranbaxy Laboratories
  • Sanofi India
  • Sun Pharmaceutical

人口結構的預測

詞彙表

分析方法

  • 醫藥品支出額的預測模式
  • 醫療費的預測模式
  • 分析方法的相關註記
  • 風險/利潤、等級技術
  • 等級概要
  • 指標的加權

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 1748-1937

BMI View: India's pharmaceutical market will continue to see more biosimilar products being launched by domestic drugmakers. Developing such products is a business necessity for Indian firms to maintain revenue growth as commoditisation limits the commercial opportunities from simple chemical molecules. This dovetails with their improving scientific and manufacturing ability, posing a pertinent threat to originator pharmaceutical firms that have product portfolios dominated by biologics.

Headline Expenditure Projections

  • Pharmaceuticals: INR1,066bn (USD17bn) in 2015 to INR1,191bn (17bn) by 2016; +11.8% in local currency terms and 5.1% in US dollar terms. Forecast unchanged from last quarter.
  • Healthcare: INR6,695bn (USD104bn) in 2015 to INR7,561bn (USD111bn) by 2016; +12.9% in local currency terms and 6.2% in US dollar terms. Forecast revised upwards from last quarter.

Table of Contents

BMI Industry View

  • Table: Headline Pharmaceuticals & Healthcare Forecasts (India 2014-2020)

SWOT

Industry Forecast

  • Pharmaceutical Market Forecast
    • Table: Pharmaceutical Sales, Historical Data And Forecasts (India 2012-2020)
  • Healthcare Market Forecast
    • Table: Healthcare Expenditure Trends, Historical Data And Forecasts (India 2012-2020)
    • Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (India 2012-2020)
    • Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (India 2012-2020)
  • Prescription Drug Market Forecast
    • Table: Prescription Drug Market Indicators, Historical Data And Forecasts (India 2012-2020)
  • Patented Drug Market Forecast
    • Table: Selected Patent Developments Affecting Drugmakers
    • Table: Patented Drug Market Indicators, Historical Data And Forecasts (India 2012-2020)
  • Generic Drug Market Forecast
    • Table: Generic Drug Market Indicators, Historical Data And Forecasts (India 2012-2020)
  • OTC Medicine Market Forecast
    • Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (India 2012-2020)
  • Pharmaceutical Trade Forecast
    • Table: Pharmaceutical Trade Data And Forecasts (India 2014-2020)
    • Table: Pharmaceutical Trade Data And Forecasts local currency (India 2014-2020)

Industry Risk/Reward Index

  • Asia Pacific Risk/Reward Index - Q4 2016
  • India Risk/Reward Index
    • Rewards
    • Risks

Regulatory Review

  • Intellectual Property Issues
    • Table: History Of The Indian Patent System
    • Table: Special 301 Submission: Issues Raised For India
    • Table: A Series Of Setbacks For Innovative Pharmaceutical Firms
  • Pricing Regime

Market Overview

  • Healthcare Sector
    • Table: Healthcare Resources (India 2010-2015)
    • Table: Healthcare Personnel (India 2010-2015)
    • Table: Healthcare Activity (India 2010-2015)
  • Research & Development
  • Clinical Trials
  • Epidemiology
    • Table: Estimated Number Of New Cases Of Cancer In India

Competitive Landscape

  • Research-Based Industry
    • Table: Ordinary Members Of OPPI
    • Table: Multinational Market Activity
  • Pharmaceutical Distribution
  • Pharmaceutical Retail Sector

Company Profile

  • Aurobindo Pharmaceutical
  • Cipla
  • Dr. Reddy's Laboratories
  • GlaxoSmithKline
  • Merck & Co
  • Novartis
  • Pfizer
  • Sanofi India
  • Sun Pharmaceutical

Demographic Forecast

  • Table: Population Headline Indicators (India 1990-2025)
  • Table: Key Population Ratios (India 1990-2025)
  • Table: Urban/Rural Population & Life Expectancy (India 1990-2025)
  • Table: Population By Age Group (India 1990-2025)
  • Table: Population By Age Group % (India 1990-2025)

Glossary

Methodology

  • Pharmaceutical Expenditure Forecast Model
  • Healthcare Expenditure Forecast Model
  • Notes On Methodology
  • Risk/Reward Index Methodology
  • Index Overview
    • Table: Pharmaceutical Risk/Reward Index Indicators
  • Indicator Weightings
Back to Top